MicroRNA-10b与早期乳腺浸润性导管癌的临床及预后研究

Relationships of miR-10b expression with clinical parameters and prognosis in patients with early breast invasive ductal carcinoma

摘要:

目的  探讨早期乳腺浸润性导管癌中microRNA-10b（miR-10b）表达与临床指标及预后关系。 方法  采用原位分子杂交技术，检测305例中早期乳腺浸润性导管癌组织miR-10b表达，采用Pearsonχ2检验分析miR-10b表达在不同临床指标间的差异性；采用Spearman秩和相关分析早期乳腺浸润性导管癌中miR-10b、年龄、淋巴结、雌激素受体α（ERα）、孕激素受体（PR）及人类表皮生长因子受体2（HER-2）之间的相关性。采用Kaplan-Meier法计算累计无瘤生存时间，应用Log-rank检验比较miR-10b不同表达组间无瘤生存时间的差异。结果  早期乳腺浸润性导管癌中miR-10b表达与年龄、肿瘤大小和复发转移，差异具有统计学意义（P <0.05）；与月经状态、临床分期、化疗、放疗及内分泌治疗比较，差异无统计学意义（P >0.05）。miR-10b阳性表达与HER-2阳性表达呈正相关，差异有统计学意义（P <0.05）。miR-10b表达阴性中位无瘤生存时间较miR-10b表达阳性时间长，两者比较差异有统计学意义（P <0.05）；淋巴结阴性时miR-10b阴性表达的中位无瘤生存时间较阳性表达长，两者比较差异有统计学意义（P <0.05）；相反，miR-10b表达在淋巴结阳性中位无瘤生存时间无统计学意义（P >0.05）。结论  miR-10b表达水平与早期乳腺浸润性导管癌复发转移相关，特别在无淋巴结转移且miR-10b阳性表达组的中位无瘤生存时间短，预后差。miR-10b阳性表达是早期乳腺浸润性导管癌的预后因素。

Abstract:

Objective To discuss the reationships of clinical parameters and prognosis of early breast invasive ductal carcinoma with miRNA-10b (miR-10b) expression. Methods In situ molecular hybridization technique was used to detect miR-10b expression in early breast invasive ductal cancer tissues of 305 cases. Pearson Chi-square test was adopted to analyze the differences in miR-10b expression between the patients with different clinical indicators. Spearman rank test was used to analyze the correlations of miR-10b expression with age, lymph node metastasis, estrogen receptor α (ERα), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) in early breast invasive ductal cancer. Kaplan-Meier method was adopted to calculate the accumulative tumor-free survival time. Log-rank test was applied to compare the tumor-free survival time between the groups with different miR-10b expressions. Results There were significant differences in age, tumor recurrence and metastasis between the early breast invasive ductal cancer patients with different miR-10b expressions (P < 0.05); however, there was no significant difference in menstrual status, clinical stage, chemotherapy, radiotherapy or endocrine therapy (P > 0.05). Positive miR-10b expression was positively correlated with positive HER-2 expression (P < 0.05). The median survival time of the patients with negative miR-10b expression was significantly longer than that of the patients with positive miR-10b expression (P < 0.05). When there was no lymph node metastasis, the median tumor-free survival time of the patients with negative miR-10b expression was significantly longer than that of the patients with positive miR-10b expression (P < 0.05); while there was no statistical difference in the median tumor-free survival time when there was lymph node metastasis (P > 0.05). Conclusions miR-10b expression level is associated with recurrence and metastasis of early breast invasive ductal carcinoma, especially in the absence of lymph node metastasis; and in the miR-10b positive expression group the median tumor-free survival time is short, the prognosis is poor. miR-10b positive expression is a prognostic factor of early breast invasive ductal cancer.